VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ETON
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ETONEton Pharmaceuticals, Inc.
$61.99$1.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ETON logo

Eton Pharmaceuticals, Inc.

ETON
NASDAQ · Rare Disease Biotech
$61.99
At close - Nov 18, 4:00 PM EST - USD
Market Cap$1.7B
P/E41.4x
52W High$70.64
Volume476.03K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Eton Pharmaceuticals Margin Rebuild Faces Sustainability Test

Eton Pharmaceuticals' revenue rose from $9.1M in 2024Q2 to $57.9M in 2026Q3, with gross margin expanding to 76.5%, suggesting a shift toward higher-value controlled products and an orphan-drug portfolio gaining scale.

GrowthAccelerating
ProfitabilityModerate
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

ETON price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

+57% Peers

P/E is 57% above peer median

03

Market leadership

RS 98 · Leader

High momentum (Outperforming 98% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ETON+281.24%
S&P 500 (^GSPC)+6.88%
1-Year Return
ETON+260.41%
S&P 500 (^GSPC)+10.62%
3-Year Return
ETON+1699.42%
S&P 500 (^GSPC)+61.02%
5-Year Return
ETON+1271.46%
S&P 500 (^GSPC)+54.88%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
41.4x
Forward P/E
57.0x
EV/EBITDA0th %ile
37.3x
FCF YieldCash Flow
2.3%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
41.4x
N/A
N/A
EV/EBITDA
37.3x
111.8x
0th· Low
Price/FCF
44.4x
44.6x
50th· Fair
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$80M+104.9% YoY
Net income FY25
-$5M-20.4% YoY
Free cash flow FY25
$10M+980.7% YoY
Operating margin FY25
0.1%+6.7 pts YoY
ROIC (FY25)0.2%
Avg ROIC 5Y-37.5%
ROE (TTM)104.8%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$0.50+60.0%
vs $0.31
$58M+38.0%
vs $42M
Q3 2026
Aug 13, 2026
$0.35+84.4%
vs $0.19
$38M+38.7%
vs $27M
Q2 2026
May 14, 2026
$0.05-50.0%
vs $0.10
$24M+8.8%
vs $22M
Q2 2026
Mar 19, 2026
$0.05-58.3%
vs $0.12
$21M+6.5%
vs $20M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·2d ago
Eton Pharmaceuticals: The Commercial Model Is Finally Scaling

Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA margin; 2026 revenue guidance increased to more than $175 million. LIBERVANT and ASN-001 are the main growth drivers, with potential launches in 2027 and 2028, respectively.

Zacks Investment Research·Nov 6, 2026
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.

MarketBeat·Nov 6, 2026
Eton Pharmaceuticals Q3 Earnings Call Highlights

Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.

Seeking Alpha·Nov 5, 2026
Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript

Filtered for Eton Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark ETON against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Eton Pharmaceuticals, Inc. (ETON)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ETON logoETONEton Pharmaceuticals, Inc.Current
$61.99$1.7B41.35104.94%35.35%104.82%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
TLRY logoTLRYTilray Brands, Inc.
$2.25$300.02M-1.8311.46%-17.05%-9.54%—
MNPR logoMNPRMonopar Therapeutics Inc.
$70.75$473.96M-29.40——-15.52%—
KALA logoKALAKALA BIO, Inc.
$3.26$8.06K-0.00——-222.32%—
LNTH logoLNTHLantheus Holdings, Inc.
$102.00$6.64B25.850.5%17.28%21.72%—

Compare ETON vs Peers

Eton Pharmaceuticals, Inc. (ETON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PRAX

Most directly comparable listed peer for ETON.

Scale Benchmark

vs MCK

Larger-name benchmark to compare ETON against a more recognizable public peer.

Peer Set

Compare Top 5

vs PRAX, TLRY, MNPR, KALA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ETON SEC Filings & Documents

Eton Pharmaceuticals, Inc. (ETON) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Nov 5, 2026·SEC

Material company update

Nov 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 19, 2026·SEC

FY 2025

Mar 18, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 13, 2026·SEC

FY 2026

May 14, 2026·SEC

Get notified when ETON posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ETON Frequently Asked Questions

Eton Pharmaceuticals, Inc. (ETON) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Eton Pharmaceuticals, Inc.'s revenue?

Eton Pharmaceuticals, Inc. (ETON) reported $141.1M in revenue over the trailing twelve months. Revenue was $80.0M in fiscal year 2025.

How fast is Eton Pharmaceuticals, Inc. growing?

Eton Pharmaceuticals, Inc. (ETON) grew revenue by 100.6% over the trailing twelve months, compared with the twelve months before.

Is ETON profitable?

Yes. Eton Pharmaceuticals, Inc. (ETON) earned $49.9M in net income over the trailing twelve months (a 35.3% net margin).

Dividend & Returns
What is ETON's return on equity?

Eton Pharmaceuticals, Inc. (ETON) had a return on equity (ROE) of 104.8% over the trailing twelve months. That is well above the market's typical 10-15%.

What is Eton Pharmaceuticals, Inc.'s free cash flow?

Eton Pharmaceuticals, Inc. (ETON) generated $38.2M in free cash flow over the trailing twelve months.

What if you invested $1,000 in ETON back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →